info@nano-mab.com

About info nano-mab

This author has not yet filled in any details.
So far info nano-mab has created 9 blog entries.

NanoMab Announces First Patient Dosed in Phase II Clinical Trial of Novel Radiolabelled Single Domain Antibody (NM-01) in Patients with Non-Small Cell Lung Cancer

2022-05-17T17:02:00+00:00

London, May 17, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on the development of next generation radiopharmaceuticals for cancer precision therapies, today announced the dosing of the first patient in a phase II clinical trial in partnership with Lantheus and King’s College London. The phase II trial is a non-randomised, non-blinded, [...]

NanoMab Announces First Patient Dosed in Phase II Clinical Trial of Novel Radiolabelled Single Domain Antibody (NM-01) in Patients with Non-Small Cell Lung Cancer2022-05-17T17:02:00+00:00

NanoMab Announces Strategic Leadership Changes

2022-04-29T14:52:04+00:00

London, April 29th, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is thrilled to announce the well-deserved promotion of Dr. Gitasha Chand to Managing Director and Dr. Levente Meszaros to Director of Technical Operations of NanoMab Technology (UK) Ltd. Dr. Chand, who most recently held the position of [...]

NanoMab Announces Strategic Leadership Changes2022-04-29T14:52:04+00:00

NanoMab Technology Limited signs licensing agreements with Radiopharm Theranostics and Full Life Technologies (HK) Ltd.

2022-04-12T15:39:24+00:00

London, April 12th, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is delighted to announce that over the course of the last two quarters it has taken the next steps forward in its commitment to developing next generation pharmaceuticals by forming exclusive licensing agreements with Radiopharm Theranostics (ASX: [...]

NanoMab Technology Limited signs licensing agreements with Radiopharm Theranostics and Full Life Technologies (HK) Ltd.2022-04-12T15:39:24+00:00

NanoMab receives MHRA approval to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging.

2020-11-05T02:54:55+00:00

London, November 4th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product. The study (“PELICAN”) will investigate the assessment of programmed death [...]

NanoMab receives MHRA approval to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging.2020-11-05T02:54:55+00:00

NanoMab and OncoBeta outline the pathway to a Strategic Alliance and Supply Agreement, focused on the secure supply of Rhenium-188 for NanoMab’s range of Therapeutic Radiopharmaceuticals

2020-10-27T01:58:31+00:00

London, October 27th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on precision cancer therapies, today announced that it had signed Heads of Terms with OncoBeta® GmbH, a supplier of Tungsten-188/ Rhenium-188 generators for the production of high-energy beta emitting Rhenium-188, as well as a commercial stage medical device company specialized in innovative [...]

NanoMab and OncoBeta outline the pathway to a Strategic Alliance and Supply Agreement, focused on the secure supply of Rhenium-188 for NanoMab’s range of Therapeutic Radiopharmaceuticals2020-10-27T01:58:31+00:00

NanoMab announces the commencement of the NM-01 mechanistic study (SPECT/CT radiotracer) for non-small cell lung cancer patients.

2020-10-09T08:28:07+00:00

London, October 8th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that in collaboration with King’s College London and Guys & St Thomas’ Hospitals, it has commenced a mechanistic study to noninvasively assess PD-L1 expression using 99mTc-NM-01 as a SPECT/CT radiotracer. Professor Gary Cook, Professor of PET [...]

NanoMab announces the commencement of the NM-01 mechanistic study (SPECT/CT radiotracer) for non-small cell lung cancer patients.2020-10-09T08:28:07+00:00

NanoMab Submits a request to the MHRA to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging

2020-09-10T06:52:58+00:00

London, September 9th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had submitted a request to the MHRA for authorisation for a Phase II Clinical Study Protocol for its NM-01 product. The study will investigate the assessment of programmed death ligand 1 (PD-L1) expression using [...]

NanoMab Submits a request to the MHRA to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging2020-09-10T06:52:58+00:00